Compare Crispr Therapeutics AG (CRSP) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Valero Energy Corporation — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while Valero Energy Corporation trades at $290.79 (market cap $89.50B). The key difference: Valero Energy Corporation is far larger — about 18× Crispr Therapeutics AG's market cap, and Valero Energy Corporation pays a 1.59% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VLO | |
|---|---|---|
Market Cap | $4.97B | $89.50B |
Sector | Health | Energy |
52-Week High | $76.78 | $301.43 |
52-Week Low | $44.34 | $131.77 |
Enterprise Value | $3.32B | $95.26B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Valero Energy (VLO) trades at $295.79, up 5.38% in the last session, reflecting strong momentum amid bullish technical signals and positive earnings surprises. The stock's valuation metrics, including a P/E of 20.5 and P/S of 0.69, appear reasonable relative to historical levels, while profitability remains solid with a 17.72% ROE. Recent news highlights VLO's exposure to elevated refining margins and strong fuel demand, particularly benefiting its Gulf Coast operations.
The outlook for VLO is supported by robust refining fundamentals and a favorable analyst consensus, though risks include volatile energy markets and declining revenue trends. Upside potential exists if the company continues to exceed earnings expectations and capitalizes on tight product supplies, but investors should monitor margin pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
